Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-031846
Filing Date
2024-08-14
Accepted
2024-08-14 07:05:58
Documents
78
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1996672
2 ex10-5.htm EX-10.5 282506
3 ex10-6.htm EX-10.6 202961
4 ex31-1.htm EX-31.1 20211
5 ex31-2.htm EX-31.2 19656
6 ex32-1.htm EX-32.1 11808
  Complete submission text file 0001493152-24-031846.txt   10225641

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE evfm-20240630.xsd EX-101.SCH 58930
8 XBRL CALCULATION FILE evfm-20240630_cal.xml EX-101.CAL 65858
9 XBRL DEFINITION FILE evfm-20240630_def.xml EX-101.DEF 310740
10 XBRL LABEL FILE evfm-20240630_lab.xml EX-101.LAB 506665
11 XBRL PRESENTATION FILE evfm-20240630_pre.xml EX-101.PRE 423941
81 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1815417
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36754 | Film No.: 241204108
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)